Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 28 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Durvalumab with bevacizumab and chemotherapy for treating advanced ovarian cancers	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Ovarian cancer	Female Reproductive Cancer	2023	View \| Download
Durvalumab with carboplatin and paclitaxel with or without olaparib for newly diagnosed advanced or reccurent endometrial cancer	Carboplatin (Paraplatin) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Paclitaxel (Taxol; paclitaxel albumin)	Endometrial cancer	Female Reproductive Cancer	2023	View \| Download
Durvalumab with fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer	5-Fluorouracil , Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Leucovorin , Oxaliplatin	Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2023	View \| Download
Durvalumab with gemcitabine-cisplatin neoadjuvant treatment and durvalumab adjuvant treatment for muscle-invasive bladder cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Bladder cancer	Urological Cancer	2022	View \| Download
Durvalumab with or without tremelimumab in addition to platinum based chemotherapy for extensive-stage disease small-cell lung cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2019	View \| Download
Durvalumab with platinum-based chemotherapy for the neoadjuvant/adjuvant treatment of resectable non-small-cell lung cancer	Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Durvalumab with transarterial chemoembolisation for hepatocellular carcinoma	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Transarterial Chemoembolisation (TACE)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Durvalumab with tremelimumab for limited stage small-cell lung cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2022	View \| Download